Metabolic effects of Tofogliflozin are efficiently enhanced with appropriate dietary carbohydrate ratio and are distinct from carbohydrate restriction
- Shiori Ito, Toshio Hosaka, +9 authors Hitoshi Ishida
- Physiological reports
- 2018
2 Excerpts
The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE −/− mice fed a western diet
- Published 2016 in Diabetologia
Abstract
A recent large clinical study has shown that empagliflozin has a lower rate of cardiovascular and all-cause mortality when compared with placebo in patients with type 2 diabetes. We investigated the effect of empagliflozin (compared with glimepiride) on the progression of atherosclerosis, and its possible mechanisms of action. Forty-eight 5-week-old male… (More)
Topics
- empagliflozin
- Atherosclerosis
- glimepiride
- Apolipoprotein E
- Sodium Chloride
- mg/kg
- Glucose
- Aortic arch structure
- Adiponectin
- Diabetes Mellitus, Non-Insulin-Dependent
- Insulin Resistance
- Diabetes Mellitus
- Plaque, Atherosclerotic
- Body Composition
- Adipose tissue
- Monocytes
- Serum amyloid A protein
- Adipocytes
- Senile Plaques
- Dual-Energy X-Ray Absorptiometry
- Infiltration
- Clinical Research
- Dental Plaque
- Cell Size
9 Figures and Tables
Close
Fig. 1 Atheroma burden in the aorta of ApoE−/− mice (n= 12 per group) after 8 weeks of treatment with glimepiride or empagliflozin. (a, c) Representative images of atheromas stained using Oil Red O of the aortic arch (scale bar, 0.5 cm) (a) and aortic valve areas (scale bar, 100 μm) (c) from ApoE−/− mice. The red colour indicates plaque accumulation. (b, d) The atheromatous plaque area (% of total area) was smaller in the aortic arch (b) and aortic valve (d) of empagliflozin-treated mice compared with control or glimepiride-treated mice. Data are means ± SEM. Weight-adjusted ANCOVAwas used. *p< 0.05 vs control; †p< 0.05 vs glimepiride